What is Zacks Research's Forecast for Surmodics Q1 Earnings?

Surmodics, Inc. (NASDAQ:SRDX - Free Report) - Stock analysts at Zacks Research decreased their Q1 2027 earnings per share estimates for Surmodics in a note issued to investors on Tuesday, July 1st. Zacks Research analyst D. Dey now expects that the company will earn $0.00 per share for the quarter, down from their previous estimate of $0.01. The consensus estimate for Surmodics' current full-year earnings is $0.20 per share. Zacks Research also issued estimates for Surmodics' FY2027 earnings at $0.28 EPS.

A number of other brokerages have also recently weighed in on SRDX. Needham & Company LLC reiterated a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th. Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 price objective on the stock in a report on Friday, March 7th.

Surmodics Trading Up 3.4%

Shares of NASDAQ SRDX traded up $0.99 during trading on Wednesday, hitting $29.99. 140,852 shares of the company traded hands, compared to its average volume of 228,483. The firm has a market capitalization of $428.79 million, a P/E ratio of -21.57 and a beta of 1.31. The company has a quick ratio of 3.99, a current ratio of 5.14 and a debt-to-equity ratio of 0.27. The company has a 50-day moving average price of $28.89 and a 200-day moving average price of $31.75. Surmodics has a 1 year low of $26.00 and a 1 year high of $42.44.

Surmodics (NASDAQ:SRDX - Get Free Report) last released its earnings results on Wednesday, April 30th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of ($0.06) by ($0.07). Surmodics had a negative net margin of 16.34% and a negative return on equity of 7.10%. The business had revenue of $28.09 million during the quarter, compared to analyst estimates of $32.23 million.

Institutional Investors Weigh In On Surmodics

Several large investors have recently made changes to their positions in the business. Millennium Management LLC lifted its holdings in shares of Surmodics by 0.4% during the 4th quarter. Millennium Management LLC now owns 120,344 shares of the company's stock valued at $4,766,000 after acquiring an additional 509 shares in the last quarter. Principal Financial Group Inc. grew its stake in Surmodics by 1.8% during the 1st quarter. Principal Financial Group Inc. now owns 36,699 shares of the company's stock valued at $1,120,000 after purchasing an additional 638 shares in the last quarter. Rhumbline Advisers increased its stake in shares of Surmodics by 4.4% in the fourth quarter. Rhumbline Advisers now owns 20,250 shares of the company's stock worth $802,000 after buying an additional 861 shares during the last quarter. Legal & General Group Plc raised its stake in shares of Surmodics by 34.2% in the 4th quarter. Legal & General Group Plc now owns 3,452 shares of the company's stock valued at $137,000 after purchasing an additional 880 shares in the last quarter. Finally, Inspire Investing LLC raised its stake in Surmodics by 11.3% during the first quarter. Inspire Investing LLC now owns 11,250 shares of the company's stock valued at $343,000 after buying an additional 1,142 shares in the last quarter. Institutional investors and hedge funds own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).